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Abstract
Introduction
Pain is a common symptom in cancer patients, and its control and management are com-
plex. Despite the high concomitant use of psychotropic drugs among such patients, the
association among pain, inadequate pain control, and psychotropic drug use has not been
fully determined. This study examined the prevalence of cancer pain and inadequate pain
control and the association with psychotropic drug use.
Materials and methods
In this cross-sectional study, we investigated 402 medical records obtained by simple ran-
dom sampling of oncology patients at a hospital in northern Spain from July 2012 to July
2014. Adjusted odds ratios (ORs) were estimated together with their 95% confidence inter-
vals (95% CIs) by unconditional logistic regression for each type of psychotropic drug (anxi-
olytics, hypnotics, and antidepressants).
Results
The mean patient age was 61.17 (standard deviation ± 13.14) years; 57.5% were women,
42.5% men. Pain was present in 18.4% of patients and inadequate pain control in 54.2%.
We found a statistically significant association between the presence of cancer pain and
anxiolytic use (adjusted OR, 3.15; 95% CI, 1.49–6.68) and hypnotic use (adjusted OR, 5.19;
95% CI, 1.77–15.25). Inadequate pain control was associated to a greater extent with the
use of those drugs: adjusted OR for anxiolytic use, 4.74 (95% CI, 1.91–11.80); adjusted OR
for hypnotic use, 6.09 (95% CI, 1.74–21.32). By contrast, no association was found between
pain and antidepressant use (adjusted OR, 0.99).
Conclusion
The presence of pain and (to a greater extent) poor pain control were associated with
increased use of certain psychotropic drugs, such as anxiolytics and hypnotics. There
appeared to be no association between pain and antidepressant use.
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Introduction
The International Association for the Study of Pain defines pain as an ‘unpleasant sensory and
emotional experience associated with actual or potential tissue damage, or described in terms
of such damage’ [1]. There is no universally accepted definition for ‘cancer pain’; however, a
high percentage of cancer patients experience pain that often cannot be controlled [2–4].
According to estimates, 20%–50% of cancer patients suffer from pain [5]; the proportion rises
to 90% in advanced stages [6]. The origin of pain is variable: it may be due to the disease itself,
aspects derived from treatment, or associated comorbidities [7]. A review of 46 studies pub-
lished between 1987 and 2007 reported that on average, pain was undertreated in 43.4% of
cancer patients; however, the figure could be as high as 82% [4]. A later review reported that
31.8% of patients had inadequately controlled pain, with poor control rising to almost 70% [3].
Pain is thus a fundamental aspect in the treatment of cancer patients. That point was estab-
lished at the 58th World Health Assembly on Cancer Prevention and Control of the World
Health Organization (WHO). The assembly concluded that pain relief and palliative care
should be prioritized in world cancer programmes; it urged health-care systems to establish
programmes for monitoring pain control [8].
The treatment and control of cancer pain is complex; authorities struggle to reach consen-
sus regarding the treatment of choice [7,9]. The European Oncology Nursing Society proposes
re-evaluating patients to ensure the efficacy of treatment [7,10]; individualized treatment for
each patient is of course recommended [2]. Since 1986, the WHO has considered psychotropic
drugs to be an adjunctive treatment for pain in cancer patients [11]. In their guidelines on
managing cancer pain, the American Cancer Society [12] and European Society for Medical
Oncology [13] currently include the use of psychotropic drugs to help relieve pain (antidepres-
sants and benzodiazepines). Psychotropic drugs may enhance the effect of pain medicines (or
lessen their side effects)—especially in the case of refractory pain. Accordingly, optimal pain
control could be associated with the use of these medicines.
Psychotropic drugs are commonly used in combination with analgesics in oncological
patients. In a study of women with breast cancer and pain, Syrowatka et al. [14] reported con-
sumption of 50.6% and 22.4%, respectively, of anxiolytics and antidepressants during the
course of active treatment. In a sample of patients with metastatic cancer and pain, Barry et al.
[15] observed anxiolytic and antidepressant consumption, respectively, in 51% and 64% of
cases. The authors found that 38% of the patients consumed three or more psychotropic drugs.
Together with the basal situation of the patient, this consumption of analgesics and psychotro-
pic drugs could increase the appearance of adverse effects. It is therefore recommended that
such patients be carefully monitored [16–18]; it may be necessary to replace the psychotropic
drugs with psychological or behavioural interventions [14].
Around one-third of cancer patients are estimated to experience some type of mental health
problem during the course of active treatment [17,18]. The complex oncological process occa-
sionally causes patients to suffer major emotional distress [19–21]: symptoms of anxiety (20%)
and depression (13%) predominate; they are sometimes accompanied by physical symptoms,
such as insomnia and headache [22,23]. This leads to increased use of psychotropic drugs.
Emotional distress in cancer patients is usually associated with pain [21,24]. Consequently,
the use of psychotropic drugs may also be related to the presence of pain or be exacerbated by
poor pain control. However, the effect of pain or poor pain control on symptoms (anxiety,
depression, and insomnia) and psychotropic drug use is not fully established. Accordingly, the
aim of the present study was to determine the prevalence of cancer pain and inadequate pain
control in cancer patients; the study also analysed the association among pain, poor pain con-
trol, and psychotropic drug use.
Inadequate cancer pain control and psychotropic drug use
PLOS ONE | https://doi.org/10.1371/journal.pone.0178742 June 8, 2017 2 / 15
Competing interests: The authors have declared
that no competing interests exist.
Materials and methods
The study protocol was approved by the Cantabria Clinical Research Ethics Committee on 29
May 2014; that was before data acquisition, which began in February 2015. The relevant autho-
rization was also obtained in line with hospital regulations. The data were treated anony-
mously and confidentially under Spanish Organic Law 15/1999 of 13 December on Personal
Data Protection. Because the data were analysed anonymously, it was not necessary to obtain
the consent of patients to investigate their data. This study received the 16th National Nursing
Research Award Valdecilla, which funds social work in Caja Cantabria (Spain). The funders
had no role in the study design, data collection and analysis, decision to publish, or prepara-
tion of the manuscript.
Study design and participants
In this cross-sectional study, the eligibility criteria were patients aged over 18 years with onco-
logical disease treated at the Oncology Unit of Hospital University Marque´s of Valdecilla
(National Public Health System of Spain) in northern Spain between 1 July 2012 and 1 July
2014. In all, 420 Oncology Unit patients were selected by simple random sampling. We consid-
ered the medical records incomplete when information about all the variables related to pain
and the use of each type of psychotropic drug was missing. We considered the records com-
plete if they contained information about >80% of the remaining variables. If the medical rec-
ords were incomplete, we withdrew the patient from the study. Of the 420 original subjects, we
removed 18 patients (4.3%) in this way (Fig 1).
To determine the sample size, we used the following criteria. With respect to prevalence,
the literature is scarce, and so we calculated the sample size by assuming maximum indetermi-
nacy (P = 0.5). Under that assumption, with a 95% confidence interval for a maximum error of
5%, we estimated a sample of 400 patients. That sample size (n = 400) would have sufficient
power (1 – β>80%) to detect associations1.3 as significant for a 50% risk of the effect in the
unexposed sample, considering an unexposed/exposed ratio of 1, using a two-tailed chi-square
test with an alpha level of 0.05.
Data sources and variables
We collected data between February and May 2015. From patient medical records and nursing
assessments, we obtained information for each cancer patient included who underwent active
treatment from 1 July 2012 to 1 July 2014. We obtained full oncological details. We collected
the following variables:
• Sociodemographic: age, sex, and education level.
• Family background: marital status and number of children [25].
• Oncological process: type of cancer (location), cancer treatment (chemotherapy, radiother-
apy, hormone therapy, biological therapy, surgery), and side effects of cancer treatment. The
symptoms considered side effects were those established by the National Cancer Institute
[26]. S1 Appendix.
• Pain: presence of pain, location of pain, intensity of pain, and pain control. The presence of
pain was treated dichotomously (yes/no). In patients whose pain was treated with analgesics,
the type of analgesic, route of administration, and intensity of pain were recorded. The latter
was measured following the recommendations of the European Society for Medical Oncol-
ogy using the Visual Analogue Scale (VAS) [13], from 0 (‘no pain’) to 10 (‘extreme pain’).
Self-perceived pain control, reported by the patients themselves, was recorded in the nursing
Inadequate cancer pain control and psychotropic drug use
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history; this information was obtained directly from the medical record. The variable ‘pain
control’ was categorized ordinally into ‘no pain’, ‘adequate pain control’, and ‘inadequate
pain control’. The Oncology Unit uses the latest recommendations of the European Society
for Medical Oncology to determine the prescription of analgesic treatment. The use of psy-
chotropic drugs was considered according to those recommendations [13]. The cancer pain
characteristics of the study population are presented in relation to sex, which may influence
pain expression [27,28].
Fig 1. Overall study flow.
https://doi.org/10.1371/journal.pone.0178742.g001
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• Use of psychotropic drugs: the use of anxiolytics, hypnotics, and antidepressants was classi-
fied dichotomously (yes/no) if a prescription for those treatments (both continuous and on
demand) was reported in the patient’s medical record.
Data analysis
The data analysis included an initial descriptive analysis. Means with their standard deviation
(SD; or median and interquartile range in the case of asymmetric distributions) were estimated
for the continuous variables using the Student t test for comparisons or the Mann-Whitney U
test in the case of non-normal distributions. We estimated proportions for the categorical and
discrete variables by means of the Pearson chi-square test, likelihood ratio (LR) chi-square test,
Wilcoxon two-sample test, and Fisher exact test as appropriate for comparisons. The use of
each type of psychotropic drug was treated as a dependent variable; we performed separate
analyses for anxiolytics, hypnotics, and antidepressants. Finally, we calculated a variable that
included the joint use of anxiolytics and hypnotics. As a measure of association, we estimated
the odds ratios (ORs) together with their 95% confidence intervals (95% CIs) by unconditional
logistic regression.
To control for confounding bias in the association between presence of pain, pain control,
and use of each psychotropic drug, we predefined the potential confounders. They were as fol-
lows: age; sex; marital status; education level; having children; type of cancer (location); che-
motherapy; radiotherapy; hormone therapy; biological therapy; surgery; side effects of cancer
treatment; and fatigue. We calculated the adjusted ORs for all the predefined potential con-
founders (maximum model). Furthermore, to obtain better precision in the adjusted estimates,
we predefined three additional criteria based on the simulation studies of Mickey and Green-
land [29] and Maldonado and Greenland[30]:
1. Associated with the presence or absence of pain with significance levels of P0.20.
2. Associated with use of the psychotropic drug under analysis with an OR of 1.5–0.67 as
criterion.
3. Causes a major change in the OR when adjusted: a change greater than 10% with the equa-
tion (ORc-ORa)/ORa >10% was considered a criterion.
For each psychotropic drug, we constructed an ad hoc optimal sub-model based on fulfil-
ment of the above three criteria. We calculated the following: crude OR (ORc); adjusted OR
(ORa) in the maximum model; and adjusted OR in the optimal sub-model.
We set the alpha error at 0.05, and all P were bilateral. All statistical analyses were per-
formed using IBM SPSS Statistics, version 22.0.
Results
Table 1 shows the pain characteristics in the sample of 402 patients according to sex.
The mean patient age was 61.17 (SD = 13.14) years; 57.5% (n = 231) were women and
42.5% (n = 171) were men. Pain was reported by 18.4% (95% CI, 14.5–22.3) of patients
(n = 74). Pain was more prevalent in men (23.4% in men, 14.7% in women; P = 0.026). With
respect to location, arthralgias were the most prevalent in both sexes, being reported by 31.1%
of patients (n = 23). The mean pain intensity, measured by the VAS, was 5.64 (SD = 1.41)
points; there were no statistically significant differences between the sexes (P = 0.621).
Among the 74 patients who reported pain, treatment was with analgesics in 72 (97.3%).
With respect to the type of analgesic, strong opioids were prescribed in 41.7% (n = 30) and
weak opioids in 5.6% (n = 4). Non-opioid analgesics were prescribed in 52.8% of patients
Inadequate cancer pain control and psychotropic drug use
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(n = 38). The most common route of administration was oral, which used in 63.9% of cases
(n = 46). With respect to pain control, among the 72 patients treated with analgesics, 45.8%
(95% CI, 33.6–58.0) (n = 33) reported adequate pain control, whereas 54.2% (95% CI, 42.0–
66.4) (n = 39) reported inadequate pain control; there were no statistically significant differ-
ences with sex (P = 0.108).
Table 2 shows the use of psychotropic drugs according to the presence of pain. In all, 40.5%
(95% CI, 28.7–52.4) (n = 30) of patients with pain reported taking some type of psychotropic
drug. With respect to the type of psychotropic drug, 32.4% used anxiolytics, 12.2% hypnotics,
and 4.1% antidepressants. The use of anxiolytics (P<0.001) and hypnotics (P = 0.004) was
Table 1. Cancer pain characteristics of the study population related to sex.
TOTAL
(N = 402)
FEMALE MALE
N = 231 57.5% N = 171 42.5%
N % N % N % p
Age (years), Mean [SD]a 61.17 [13.14] 60.08 [12.75] 62.64 [13.55] 0.053
Pain
No 328 81.6 197 85.3 131 76.6 0.026*
Yes 74 18.4 34 14.7 40 23.4
Location of pain
Arthralgias 23 31.1 12 35.3 11 27.5
Craniofacial 12 16.2 3 8.8 9 22.5
Abdominal 9 12.2 3 8.8 6 15.0
Epigastric 8 10.8 4 11.8 4 10.0
Lumbar 7 9.5 5 14.7 2 5.0
Others 15 29.3 7 20.6 8 20.0
VASb, Mean [SD]a 5.64 [1.41] 5.50 [1.28] 5.74 [1.51] 0.621**
Analgesic use
No 2 2.7 0 0 2 5.0
Yes 72 97.3 34 100.0 38 95.0
Type of analgesic
Strong Opiods 30 41.7 14 41.2 16 42.1
Weak Opiods 4 5.6 2 5.9 2 5.3
Non-opoid analgesics 38 52.8 18 25.0 20 27.8
Nonsteroidal anti-inflammatory
drugs
23 31.9 12 35.3 11 28.9
Other Non-opoid analgesics 15 20.8 6 17.6 9 22.5
Route of administration
Oral 46 63.9 23 67.6 23 60.5 0.125*
Transdermal 26 36.1 11 32.4 15 39.5
Effectiveness of
analgesia
Adequate pain control 33 45.8 17 50 16 42.1 0.108*
Inadequate pain
control
39 54.2 17 50 22 57.9
a Standard deviation
b Visual Analogue Scale
*Chi-square test
**Wilcoxon two-sample test
https://doi.org/10.1371/journal.pone.0178742.t001
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Table 2. Factors associated with presence of cancer pain.
TOTAL
(N = 402)
EXISTENCE OF CANCER PAIN
No (N = 328) Yes (N = 74)
N % N % N % p
Any psychotropic use
No 321 79.9 277 84.5 44 59.5 <0.001*
Yes 81 20.2 51 15.5 30 40.5
Anxiolytic use
No 334 83.1 284 86.6 50 67.6 <0.001*
Yes 68 16.9 44 13.4 24 32.4
Type of anxiolytic
Long-acting benzodiazepines 22 32.4 18 40.9 4 16.7 0.041*
Short-acting benzodiazepines 46 67.7 26 59.1 20 83.3
Hypnotic use
No 384 95.5 319 97.3 65 87.8 0.004***
Yes 18 4.5 9 2.7 9 12.2
Type of hypnotic
Benzodiazepines 9 50.0 5 55.6 4 44.4 >0.005****
Other 9 50.0 4 44.4 5 55.6
Antidepressant use
No 385 95.8 314 95.7 71 96.0 0.934*
Yes 17 4.2 14 4.3 3 4.1
Type of antidepresant
SSRIs a 17 100.0 14 100.0 3 100.0
Potential confounders
Gender
Female 231 57.5 197 60.1 34 46.0 0.027*
Male 171 42.5 131 39.9 40 54.1
Age (year), mean [SD] b 61.17 [13.14] 61.14 [13.50] 61.30 [11.53] 0.845**
Marital status
Married 276 77.7 229 79.5 47 70.1 0.150*
Single 50 14.1 40 13.9 10 14.9
Divorced/Separated 11 3.0 7 2.4 4 6.0
Widowed 18 5.1 12 4.2 6 9.0
Missing 47 11.7 40 12.2 7 9.5
Children
No 88 24.8 69 24.0 19 28.4
Yes 267 75.2 219 76.0 48 71.6 0.457*
Missing 47 11.7 40 12.2 7 9.5
Number of children, mean [SD] b 1.83 [1.01] 1.82 [1.04] 1.90 [0.93] 0.437**
Educational level
Primary 202 57.5 166 58.2 36 54.5 0.410*
Secondary 80 22.8 61 21.4 19 28.8
University 69 19.7 58 20.4 11 16.7
Missing 51 12.7 43 13.1 8 10.8
Type of cancer (location)
Breast 111 27.6 98 29.9 13 17.6 <0.001*
Rectal 64 15.9 56 17.1 8 10.8
(Continued )
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significantly higher among the patients with pain. Table 2 shows the potential confounders
according to the presence of pain.
Sex, the type of cancer (location), hormone therapy, and side effects of cancer treatment
were statistically significantly associated with the presence of pain. Marital status, radiother-
apy, and surgery to remove cancer were associated to a lesser degree, presenting significance
Table 2. (Continued)
TOTAL
(N = 402)
EXISTENCE OF CANCER PAIN
No (N = 328) Yes (N = 74)
N % N % N % p
Lung 37 9.2 21 6.4 16 21.6
B-cell lymphoma 30 7.5 27 8.2 3 4.1
Ovary 14 3.5 12 3.7 2 2.7
Other 146 36.3 114 34.8 32 43.2
Cancer therapy
Chemotherapy
No 37 9.2 32 9.8 5 6.8 0.420*
Yes 365 90.8 296 90.2 69 93.2
Radiotherapy
No 224 55.7 190 57.9 34 45.9 0.061*
Yes 178 44.3 138 42.1 40 54.1
Hormone therapy
No 346 86.1 277 84.5 69 93.2 0.048*
Yes 56 13.9 51 15.5 5 6.8
Biological therapy
No 278 69.2 226 68.9 52 70.3 0.818*
Yes 124 30.8 102 31.1 22 29.7
Surgery
No 212 52.7 167 50,9 45 60.8 0.124*
Yes 190 47.3 161 49.1 29 39.2
Side effects of cancer treatment
No 83 20.6 79 24.1 4 5.4 <0.001*
Yes 319 79.4 249 75.9 70 94.6
Analgesic
No 330 82,1 328 100 2 2.7 <0.001*
Yes 72 17.9 0 0 72 97.3
Effectiveness of analgesia
Adequate pain control 33 45.8 0 0 33 45.8
Inadequate pain control 39 54.2 0 0 39 54.2
Fatigue
No 206 51.2 165 50.30 41 55.4 0.507*
Yes 196 48.8 163 49.69 33 44.6
a SSRIs: selective serotonin reuptake inhibitors
b Standard deviation
*Compared using chi-square test
**Compared using Wilcoxon two-sample test
***Compared using LR chi-square test
****Compared using Fisher exact test
https://doi.org/10.1371/journal.pone.0178742.t002
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levels of P0.20. All these variables therefore met the first criterion for being included as con-
founders in the optimal models.
The association of each of these variables with taking psychotropic drugs can be seen in S1
Table. Table 3 shows the associations among the presence of pain, pain control, and anxiolytic
use. The presence of pain was statistically significantly associated with anxiolytic use: ORc,
3.10 (95% CI, 1.7–5.5). This association was strengthened after adjusting for all potential con-
founders in the maximum model: ORa maximum model, 3.64 (95% CI, 1.6–8.4; S2 Table).
The association was also strengthened after the selection of confounders included in the opti-
mum model based on established methodological criteria (sex, marital status, type of cancer
[location], and side effects of cancer treatment): ORa optimum model, 3.15 (95% CI, 1.5–6.7).
After ordinal categorization based on pain control, the associations showed a statistically sig-
nificant dose-response pattern: ORc for ‘inadequate pain control’, 4.03 (95% CI, 2.0–8.3; linear
P trend, <0.001); ORa maximum model, 4.98 (95% CI, 1.8–13.7; linear P trend = 0.001 S2
Table); and ORa optimum model, 4.74 (95% CI, 1.9–11.8; linear P trend = 0.001).
Table 4 shows the associations among presence of pain, pain control, and hypnotic use.
Statistically, the presence of pain was significantly associated with hypnotic use: ORc, 4.91
(95% CI, 1.9–12.8). This association was also strengthened after adjusting for all confounders
in the maximum model (ORa maximum model, 5.57; 95% CI, 1.6–19.0; S2 Table) and opti-
mum model (marital status and type of cancer [location]) OR optimum model, 5.19; 95% CI,
1.8–15.3). The association showed a statistically significant dose-response trend: ORc ‘inade-
quate pain control’, 5.21 (95% CI, 1.6–16.4; linear P trend = 0.002); ORa maximum model,
7.60 (95% CI, 1.8–31.3; linear P trend = 0.004; S2 Table); and ORa optimum model, 6.09 (95%
CI, 1.7–21.3; linear P trend = 0.003). By contrast, we found no association between the pres-
ence of pain and antidepressant use: ORc, 0.95 (95% CI, 0.27–3.39); ORa maximum model,
1.03 (95% CI, 0.2–4.8; S2 Table); and ORa optimum model, 0.99 (95% CI, 0.2–4.2). Details
appear in Table 5.
When we considered joint use of anxiolytics and hypnotics, we were able to determine the
associations between pain and pain control with greater precision: ORc, 3.76 (95% CI, 2.1–
6.6); ORa maximum model, 4.81 (95% CI, 2.2–10.6); and ORa optimum model, 4.20 (95% CI,
2.0–8.6). Details appear in S2 and S3 Tables.
Table 3. Association among presence of cancer pain, pain control, and anxiolytic use.
Anxiolytic use
No (n) Yes (n) ORca (95% CI) ORa optb (95% CI)
Existence of cancer pain
No 284 44 1 1
Yes 50 24 3.10 1.7 5.5 3.15 1.5 6.7
No (n) Yes (n) ORca (95% CI) ORa optb (95% CI)
Pain control
No pain 284 44 1 1
Adequate pain control 25 8 2.07 0.9 4.9 1.86 0.6 5.4
Inadequate pain control 24 15 4.03 2.0 8.3 4.74 1.9 11.8
Linear p trend <0.001 0.001
a Odds ratios and 95% confidence Intervals. ORc: crude odds ratio
b ORa opt: adjusted OR according to the optimum model (with only selection of confounders included in the regression model according to the criteria
described in Materials and Methods (P0.20; OR 1.5–0.67, change in OR, >10%): sex, marital status, type of cancer (location), and side effects of cancer
treatment
https://doi.org/10.1371/journal.pone.0178742.t003
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Discussion
In our sample, 18% of patients reported cancer pain. Pain is the symptom most commonly
reported by cancer patients with treatment, and it causes major suffering to patients and their
families [31]. Our findings are in agreement with those of Fischer et al. [5], who found the
prevalence of pain to be 20%–50% in a cancer population. However, our results are at variance
with those of other studies, which reported the prevalence to be 40%, 50%, and even 90% of
patients [6,22,32,33], depending on the type of cancer or disease stage. The findings of Fischer
et al. [5] are used as a reference by the National Cancer Institute in their latest guidelines on
cancer pain [21].
Since pain is such a widespread problem, it is particularly important to achieve effective
treatment and symptom control. However, patients are often undertreated, which negatively
affects their quality of life [21,33]. Complete, individualized patient assessment is therefore
essential; it should address their pain history and involve a physical and psychosocial examina-
tion [20,34].
Table 5. Association among presence of cancer pain, pain control, and antidepressant use.
Antidepressant use
No (n) Yes (n) ORca (95% CI) ORa optb (95% CI)
Existence of cancer pain
No 314 14 1 1
Yes 71 3 0.95 0.27 3.4 0.99 0.23 4.2
No (n) Yes (n) ORca (95% CI) ORa optb (95% CI)
Pain control
No pain 314 14
Adequate pain control 31 2 1.45 0.31 6.7 1.73 0.30 9.9
Inadequate pain control 38 1 0.59 0.08 4.6 0.54 0.06 4.9
Linear p trend 0.778 0.752
a Odds ratio and 95% confidence intervals. ORc: crude odds ratio
b ORa opt: adjusted OR according to the optimum model (with only selection of confounders included in the regression model according to the criteria
described in Materials and Methods (P0.20: OR 1.5–0.67, change in OR, >10%): sex, marital status, type of cancer (location), radiotherapy, and hormone
therapy
https://doi.org/10.1371/journal.pone.0178742.t005
Table 4. Association among presence of cancer pain, pain control, and hypnotic use.
Hypnotic use
No (n) Yes (n) ORca (95% CI) ORa optb (95% CI)
Existence of cancer pain
No 319 9 1 1
Yes 65 9 4.91 1.9 12.8 5.19 1.8 15.2
No (n) Yes (n) ORca (95% CI) ORa optb (95% CI)
Pain control
No pain 319 9 1 1
Adequate pain control 29 4 4.89 1.4 16.8 4.26 1.0 17.9
Inadequate pain control 34 5 5.21 1.6 16.4 6.09 1.7 21.3
Linear p trend 0.002 0.003
a Odds ratio and 95% confidence intervals. ORc: crude odds ratio
b ORa opt: adjusted OR according to the optimum model (with only selection of confounders included in the regression model according to the criteria
described in Materials and Methods (P0.20; OR 1.5–0.67, change in OR, >10%): marital status and type of cancer (location)
https://doi.org/10.1371/journal.pone.0178742.t004
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Pain control was inadequate in more than 50% of our patients. This proportion is similar to
that reported by Greco et al. [3] in a review of 20 articles: control was found to be inadequate
in up to 68% of patients, with a mean of 31.8%. Their data were collected from 2007 to 2013.
Greco et al. found improvement in pain control with respect to a similar review published in
2008, where undertreatment was reported in up to 82% of patients [35].
In our sample, 20% of cancer patients took some type of psychotropic drug. This result is in
line with the findings of Grassi et al. [36] in a review on mental disorders in cancer patients.
Grassi et al. determined that 25%–30% of patients met the criteria for depression, anxiety, and
insomnia (among other conditions).
Among our patients with pain, 32.4% took anxiolytics. This figure is higher than that
reported by Desplenter et al. [37] in a general cancer population. However, our figure is lower
than that determined by Syrowatka et al. [14] in a study of women with breast cancer; the
authors found that 50.6% of patients received anxiolytics in the course of active treatment. Our
figure is also lower than that reported by Barry et al. [15] among patients with metastatic can-
cer and pain; the authors observed anxiolytic use among 51% of patients. It should be noted
that Barry et al. [15] reported that 38% of patients consumed three or more psychotropic
drugs.
Although insomnia is often related to pain, only 12.2% of our patients with pain consumed
hypnotics. That is because in the present study we investigated the use of hypnotics, not the
presence of insomnia. Thus, it is possible that in our sample, many patients suffered from
insomnia but were not receiving pharmacological treatment; some studies have reported a
higher prevalence of insomnia in patients with pain [38,39]. However, that 12.2% figure is sig-
nificantly higher than the proportion of patients without pain who took psychotropic drugs,
which was 2.7% (P = 0.004).
We found that 4.1% of our patients with pain took antidepressants; that figure did not differ
from the group of patients without pain. These results are much lower than those reported by
Syrowatka et al. [14], Barry et al. [15], and Ng et al. [40]; those authors found the prevalence to
be 22.4%, 64%, and 10.8%, respectively. However, Kierner et al. [41], who studied patients
with cancer in late stages of the disease, reported that more than 75% and 90% of patients,
respectively, took psychotropic and analgesic drugs. Their finding suggests that consumption
may increase as the disease progresses
We found that the presence of pain and (to a greater extent) inadequate pain control were
associated with a higher risk of taking anxiolytics and hypnotics, but not antidepressants.
When adjusted for the optimal model, with respect to patients with no pain, the possibility
(odds) of taking anxiolytics and hypnotics increased 4.74-fold and 6.09-fold, respectively, in
patients with inadequate pain control. There are several explanations for this association. Lack
of pain control results in poorer patient quality of life and social relationships as well as in less
tolerance to cancer treatment [42]. This situation, together with the associated sleep disorders,
fatigue, anxiety, and depression [42–45], could result in increased psychotropic drug use. It
may also be the case, however, that certain psychotropic drugs are prescribed as analgesic adju-
vants for better pain control [11,24,46].
The cross-sectional nature of our study does not permit conclusions to be drawn in the
above regard. Future longitudinal studies should investigate this association in greater depth.
They should determine to what extent pain leads to more psychiatric symptoms (since that is
the reason for taking psychotropic drugs) and to what extent psychotropic drugs are prescribed
as adjuvants in the treatment of pain, without assessing psychiatric symptoms. However, the
above association suggests that if pain can be reduced—following analgesic recommendations
or using interventions based on relaxation or adaptive coping strategies [24]—the patient will
require fewer psychotropic drugs and obtain better quality of life.
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The present study shows that despite the latest recommendations [12,13], cancer patients
still have uncontrolled pain. This may be because of the following factors: the treatment and
control of cancer pain is very complex; the lack of clear consensus among experts [7,9]; the
need to re-evaluate the patient to ensure efficacy of treatment [7,10]; the need for individual-
ized treatment for each patient [2]; patients’ fear of addiction; misconceptions about pain and
illness [47]; ignorance about medical equipment in evaluating and managing pain; and lack of
access or limited access to certain analgesics [48]. All those factors contribute to less pain con-
trol. There is therefore a need to continue research in this area.
In this study, we investigated only the presence of pain and its management and control
independently of the duration. Our objective was to determine the association between pain
control and psychotropic drug use. However, we believe that future studies should address any
differences between acute and chronic pain.
In retrospective studies based on secondary information (records), the low quality of the
information—owing to either incomplete records or lack of agreement among different rec-
ords—can be a major limitation. For this reason, we selected variables that could be collected
homogeneously in secondary records. However, we were unable to obtain information about
symptoms of stress, anxiety, depression, and sleeping problems or identify the reasons for
patients having been prescribed psychotropic drugs. We only derived information about the
whole oncological situation at the time of data collection; oncological processes may, though,
in some cases continue for several years.
The protocol in this study involved checking for discrepancies (contradictory information)
individually with the physicians or nurses responsible for the patient; we conducted a sensitiv-
ity analysis by incorporating the information separately. We found 100% agreement regarding
the analysed variables.
One limitation of this study was that the small number of patients who took antidepressants
did not enable their association for inadequate pain control to be determined with sufficient
precision. One of the strengths of the study was the control of confounding bias on the associa-
tions: applying the optimal model allowed the confounding bias to be minimized with the
highest possible precision in the estimates.
In conclusion, we found the prevalence of pain in cancer patients to be almost 20%. Despite
receiving analgesic treatment, pain was inadequately controlled in over 50% of patients.
Both the presence of pain and (to a greater extent) inadequate pain control were associated
with use of anxiolytics and hypnotics. This association did not appear to exist for antidepres-
sant use.
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